Citizens Financial Group 13F: Adds $3.9M to Pfizer (PFE) Stake

Citizens Financial Group has increased its stake in Pfizer Inc. (PFE) by 137,710 shares, raising its total holdings to 446,847 shares. This move was disclosed in a filing on October 23, 2026, with a reported value of approximately $12.7 million.

PFE Pfizer Inc.

$30.03 ▲ +25.44% year to date

1M 3M YTD

Daily close · Oct 23, 2026

What Changed in Citizens Financial Group's Pfizer Position

Citizens Financial Group's stake in Pfizer rose from 309,137 shares to 446,847 shares, a 44.5% increase. The change in value was about $3.9 million, reflecting the growing confidence in Pfizer's market position.

Where Pfizer Fits in Citizens Financial Group's Portfolio

Pfizer now makes up 0.49% of Citizens Financial Group's total reported portfolio, ranking 27th out of 1,148 positions.

Other Institutional Activity in Pfizer

Several other funds have also adjusted their positions in Pfizer recently. Tectonic Advisors grew its stake by 33,109 shares, totaling 465,200 shares worth about $13.3 million. Meanwhile, Quilter reduced its holdings by 41,417 shares, bringing its total to 621,511 shares valued at approximately $17.7 million. Brandes Investment Partners also increased its position by 478,043 shares, totaling 9,107,225 shares worth about $221.9 million.

Pfizer Inc. Stock Down 2.1%

Pfizer's shares closed at $30.03 on October 23, 2026, while they recently traded around $29.79 as of October 27, 2026. The stock is currently below its 52-week high of $30.44 but above its low of $23.62. It is also trading above both its 50-day and 200-day moving averages.

Recent Earnings

Pfizer reported trailing twelve-month revenue of approximately $63.7 billion, with a net margin of 6.8% and an earnings per share (EPS) of $0.76. The company is set to release its next earnings report on November 3, 2026.

Dividend

Pfizer pays an annual dividend of $1.72 per share, which translates to a yield of 5.73%. The company's dividend payout ratio is notably high at 226.3%.

Insider Buying and Selling at Pfizer Inc.

Recently, several insiders purchased shares of Pfizer. Shantanu Narayen bought 2,059 shares at an average price of $24.29 on June 26, 2026, totaling about $50,013. Similarly, other insiders like Cyrus Taraporevala and Joseph Echevarria also made purchases on the same date, indicating their confidence in the company.

Analysts Set New Price Targets

On August 7, 2026, Guggenheim maintained a "Buy" rating on Pfizer with a price target of $31.00, while HSBC maintained a "Hold" rating with a target of $30.00 on September 10, 2026. The consensus among analysts suggests a generally positive outlook for Pfizer, with 26 opinions rating it as a buy.

About Pfizer Inc.

Pfizer Inc. is a major player in the healthcare sector, focusing on discovering, developing, and selling biopharmaceutical products globally. Its diverse product range spans several segments, including Biopharma, PC1, and Pfizer Ignite, making it a significant entity in the drug manufacturing industry.

Bottom Line

Investors will be watching Pfizer closely as it prepares for its next earnings report on November 3, 2026. Citizens Financial Group's recent increase in its stake reflects a growing confidence in Pfizer's prospects, while other funds are also adjusting their positions. The stock's performance relative to its moving averages and the upcoming earnings could provide further insights into its market trajectory.